Stratec Biomedical AG (SBS) Given a €58.00 Price Target at Oddo Securities

Oddo Securities set a €58.00 ($68.24) price objective on Stratec Biomedical AG (ETR:SBS) in a research report released on Monday, July 24th. The brokerage currently has a neutral rating on the stock.

Shares of Stratec Biomedical AG (ETR:SBS) traded down 0.51% on Monday, hitting €50.66. The stock had a trading volume of 103 shares. Stratec Biomedical AG has a one year low of €41.45 and a one year high of €63.18. The stock has a market capitalization of €602.25 million and a PE ratio of 31.29. The firm’s 50 day moving average is €54.08 and its 200-day moving average is €54.42.

TRADEMARK VIOLATION WARNING: This report was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/08/19/stratec-biomedical-ag-sbs-given-a-58-00-price-target-at-oddo-securities-updated-updated-updated.html.

Stratec Biomedical AG Company Profile

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other Segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical AG (ETR:SBS)

What are top analysts saying about Stratec Biomedical AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stratec Biomedical AG and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit